Work

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α).

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.4594

Authors: S. Patil, R. A. Figlin, T. E. Hutson, D. Michaelson, S. Negrier, S. T. Kim, X. Huang, R. J. Motzer

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2211537226

Cites:

Cited by: 34

Related to: 10